Butterfly Network and Rutgers Robert Wood Johnson Medical School Reveal Preliminary Findings from Seminal Study on Impact of POCUS in Hospital Care
Butterfly Network (NYSE: BFLY) announced preliminary findings from a key study conducted with Rutgers Robert Wood Johnson Medical School, showing significant benefits of point-of-care ultrasound (POCUS) in hospital care. The study, presented at EchoEuro-Imaging Conference, focused on using cardiopulmonary POCUS for patients with unexplained shortness of breath.
The research compared hospital physicians using Butterfly iQ+ and iQ3 POCUS devices versus those not using POCUS. Key findings revealed substantial reductions in hospital length of stay (LOS): lower-acuity patients' LOS decreased from 6.7 to 5.6 days, while higher-acuity patients saw reduction from 39 to 16.7 days. Lower-acuity patients experienced up to 50% cost reduction. Daily lung ultrasound usage was identified as important for accelerating patient discharge.
The complete study is expected to be published in the first half of 2025.
Butterfly Network (NYSE: BFLY) ha annunciato i risultati preliminari di uno studio chiave condotto con la Rutgers Robert Wood Johnson Medical School, mostrando significativi benefici dell'ecografia point-of-care (POCUS) nella cura ospedaliera. Lo studio, presentato alla Conferenza EchoEuro-Imaging, si è concentrato sull'utilizzo della POCUS cardiopolmonare per pazienti con dispnea inspiegata.
La ricerca ha confrontato i medici ospedalieri che utilizzano i dispositivi POCUS Butterfly iQ+ e iQ3 rispetto a quelli che non utilizzano POCUS. I principali risultati hanno rivelato sostanziali riduzioni nella durata della degenza ospedaliera (LOS): la LOS dei pazienti a bassa acuità è diminuita da 6,7 a 5,6 giorni, mentre i pazienti ad alta acuità hanno visto una riduzione da 39 a 16,7 giorni. I pazienti a bassa acuità hanno registrato fino al 50% di riduzione dei costi. L'uso quotidiano dell'ecografia polmonare è stato identificato come importante per accelerare le dimissioni dei pazienti.
Lo studio completo è previsto per la pubblicazione nella prima metà del 2025.
Butterfly Network (NYSE: BFLY) anunció hallazgos preliminares de un estudio clave realizado con la Rutgers Robert Wood Johnson Medical School, mostrando beneficios significativos de la ecografía point-of-care (POCUS) en el cuidado hospitalario. El estudio, presentado en la Conferencia EchoEuro-Imaging, se centró en el uso de POCUS cardiopulmonar para pacientes con dificultad para respirar inexplicada.
La investigación comparó a los médicos del hospital que usaban los dispositivos POCUS Butterfly iQ+ e iQ3 contra aquellos que no usaban POCUS. Los hallazgos clave revelaron reducciones sustanciales en la duración de la estancia hospitalaria (LOS): la LOS de pacientes de baja acuitud disminuyó de 6,7 a 5,6 días, mientras que los pacientes de alta acuitud vieron una reducción de 39 a 16,7 días. Los pacientes de baja acuitud experimentaron hasta un 50% de reducción en costos. El uso diario de ecografías pulmonares se identificó como importante para acelerar el alta de los pacientes.
Se espera que el estudio completo se publique en la primera mitad de 2025.
버터플라이 네트워크 (NYSE: BFLY)는 러트거스 로버트 우드 존슨 의과대학과 함께 진행한 주요 연구의 예비 결과를 발표하며 병원 치료에서 포토-케어 초음파(POCUS)의 중요한 이점을 보여주었습니다. 이 연구는 설명되지 않는 호흡곤란을 겪고 있는 환자에 대한 심폐 POCUS의 사용을 중심으로 진행되었습니다.
연구는 Butterfly iQ+와 iQ3 POCUS 장비를 사용하는 병원 의사와 POCUS를 사용하지 않는 의사들을 비교했습니다. 주요 결과는 병원 입원 기간(LOS)의 상당한 감소를 밝혔습니다: 낮은 중증도의 환자의 LOS는 6.7일에서 5.6일로 감소하였고, 높은 중증도의 환자들은 39일에서 16.7일로 줄어들었습니다. 낮은 중증도의 환자들은 최대 50%의 비용 절감을 경험했습니다. 매일 실시되는 폐 초음파 사용은 환자의 퇴원을 가속화하는 데 중요하다는 것이 확인되었습니다.
완전한 연구 결과는 2025년 상반기에 발표될 예정입니다.
Butterfly Network (NYSE: BFLY) a annoncé des résultats préliminaires d'une étude clé réalisée avec la Rutgers Robert Wood Johnson Medical School, montrant des avantages significatifs de l'échographie point-of-care (POCUS) dans les soins hospitaliers. L'étude, présentée lors de la conférence EchoEuro-Imaging, s'est concentrée sur l'utilisation de la POCUS cardiopulmonaire pour les patients souffrant d'essoufflement inexpliqué.
La recherche a comparé les médecins hospitaliers utilisant les dispositifs POCUS Butterfly iQ+ et iQ3 avec ceux ne utilisant pas POCUS. Les résultats clés ont révélé des réductions substantielles de la durée de séjour à l'hôpital (LOS) : la LOS des patients de faible acuité a diminué de 6,7 à 5,6 jours, tandis que les patients de forte acuité ont vu leur LOS passer de 39 à 16,7 jours. Les patients à faible acuité ont connu jusqu'à 50 % d'économie de coûts. L'utilisation quotidienne de l'échographie pulmonaire a été jugée importante pour accélérer le congé des patients.
On s'attend à ce que l'étude complète soit publiée au cours de la première moitié de 2025.
Butterfly Network (NYSE: BFLY) gab die vorläufigen Ergebnisse einer wichtigen Studie bekannt, die mit der Rutgers Robert Wood Johnson Medical School durchgeführt wurde, und zeigte signifikante Vorteile der Point-of-Care-Ultraschalluntersuchung (POCUS) in der Krankenhausversorgung. Die Studie, die auf der EchoEuro-Imaging-Konferenz präsentiert wurde, konzentrierte sich auf die Verwendung von kardiopulmonalem POCUS bei Patienten mit unerklärlicher Atemnot.
Die Forschung verglich Krankenhausärzte, die Butterfly iQ+ und iQ3 POCUS-Geräte verwendeten, mit denen, die POCUS nicht einsetzten. Die wichtigsten Ergebnisse zeigten erhebliche Reduzierungen der Krankenhausaufenthaltsdauer (LOS): Die LOS bei Patienten mit niedrigerer Schwere verringerte sich von 6,7 auf 5,6 Tage, während die Patienten mit höherer Schwere von 39 auf 16,7 Tage reduzierten. Patienten mit niedrigerer Schwere erlebten eine Kostenreduzierung von bis zu 50%. Täglicher Lungenultraschall wurde als wichtig identifiziert, um die Entlassung der Patienten zu beschleunigen.
Die vollständige Studie wird voraussichtlich in der ersten Hälfte von 2025 veröffentlicht.
- Significant reduction in hospital length of stay by over 4 days
- Up to 50% cost reduction for lower-acuity patients
- Higher-acuity patients' length of stay reduced by 22.3 days (from 39 to 16.7 days)
- Lower-acuity patients' length of stay reduced by 1.1 days (from 6.7 to 5.6 days)
- None.
Insights
The preliminary findings from the Rutgers study represent a groundbreaking validation of POCUS technology's clinical and economic value. The demonstrated reduction in length of stay (LOS) - from 6.7 to 5.6 days for lower-acuity patients and 39 to 16.7 days for higher-acuity patients - translates to substantial operational efficiencies and cost savings for healthcare systems. The up to
Think of POCUS as a GPS for doctors - instead of waiting days for traditional imaging appointments, physicians can immediately navigate patient conditions, leading to faster diagnosis and treatment decisions. This real-time capability is revolutionizing the standard of care for respiratory patients.
The study's design as a prospective, head-to-head comparison using Butterfly's iQ+ and iQ3 devices provides robust evidence that could accelerate POCUS adoption across healthcare systems. For investors, this validates Butterfly's technology and positions the company to capture a larger share of the
This clinical validation study significantly strengthens Butterfly Network's market position and growth potential. The demonstrated cost savings and efficiency improvements directly address two critical pain points in healthcare: resource utilization and length of stay. With hospitals under increasing pressure to optimize operations and reduce costs, these results could accelerate POCUS adoption and Butterfly's device sales.
The substantial reduction in length of stay, particularly for high-acuity patients (22.3 days shorter), represents significant cost savings for hospitals. Based on average hospital costs of
From a market perspective, this data could catalyze increased institutional adoption and potentially lead to favorable reimbursement policies, creating multiple revenue growth vectors for Butterfly Network.
Study demonstrates significant reductions in length of stay and healthcare costs, advocating for broader adoption of POCUS in hospital settings.
The study focused on using cardiopulmonary POCUS for patients admitted to the hospital with shortness of breath without an identifiable cause. It was designed as a prospective, head-to-head comparison of hospital physicians who utilized Butterfly iQ+ and/or iQ3 POCUS devices versus those who did not use POCUS. Results showed a significant reduction in both hospital length of stay (LOS) and healthcare costs. Patients experienced an average LOS reduction of over four days. Lower-acuity patients saw their LOS reduced from 6.7 to 5.6 days. For higher-acuity patients, LOS was reduced from 39 to 16.7 days. These reductions also translated into substantial financial savings, with lower-acuity patients experiencing up to
Dr. Partho Sengupta, Henry Rutgers Professor of Cardiology and Chief of Cardiovascular Medicine at RWJMS and RWJUH, and principal investigator of the study, said, “This study is an important demonstration that point-of-care ultrasound can serve as a practical tool for stratifying patient acuity, reducing hospital resource utilization, and improving patient flow. The preliminary findings support the growing body of evidence advocating for POCUS as an essential component of modern hospital care and underscore the need for broader adoption of POCUS to improve outcomes and address healthcare inefficiencies.”
Daily use of lung ultrasound (LUS) emerged as a key factor in accelerating discharge for lower-acuity patients, demonstrating how this technology can facilitate more efficient and effective patient management.
“These results reflect the immense value of POCUS in enhancing care delivery and reducing the financial burden of hospitalizations,” said Dr. John Martin, Chief Medical Officer, Butterfly Network. “The integration of POCUS into hospital workflows is not just about advancing technology but about transforming the patient experience while addressing critical challenges in healthcare systems.”
The full study is anticipated to be published in the first half of 2025.
Read more about the preliminary findings at: https://www.butterflynetwork.com/rutgers-case-study. To learn more about the transformative impact of Butterfly technology, visit www.butterflynetwork.com.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113532199/en/
Butterfly Media:
Liz Learned
Head of Corporate Communications, Butterfly
media@butterflynetwork.com
Butterfly Investors:
Heather Getz
Chief Financial and Operations Officers, Butterfly
investors@butterflynetwork.com
Source: Butterfly Network, Inc.
FAQ
What are the key findings of Butterfly Network's (BFLY) Rutgers study on POCUS?
When will the full BFLY Rutgers POCUS study be published?
How much did BFLY's POCUS technology reduce hospital costs in the Rutgers study?
What devices were used in the Butterfly Network Rutgers POCUS study?
Where was the BFLY Rutgers POCUS study presented?
